PepGen Inc. (PEPG)
- Previous Close
11.83 - Open
11.61 - Bid 11.35 x 200
- Ask --
- Day's Range
10.85 - 11.67 - 52 Week Range
3.72 - 17.51 - Volume
17,325 - Avg. Volume
139,464 - Market Cap (intraday)
374.972M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.30 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.60
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
pepgen.comRecent News: PEPG
Performance Overview: PEPG
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEPG
Valuation Measures
Market Cap
382.75M
Enterprise Value
292.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.53
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.39%
Return on Equity (ttm)
-54.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-78.63M
Diluted EPS (ttm)
-3.30
Balance Sheet and Cash Flow
Total Cash (mrq)
110.41M
Total Debt/Equity (mrq)
18.54%
Levered Free Cash Flow (ttm)
-44.03M